#United States #Los Angeles #4DMedical #CTVQ #Lung Imaging

4DMedical Secures Over $100 Million in Funding

4DMedical, a prominent player in software-based respiratory imaging, has recently announced a significant funding round, raising more than US$100 million (approximately AU$150 million) through institutional placements. This substantial investment is aimed at accelerating the adoption of their innovative product, CTVQ™, across the United States while also bolstering their research and development efforts.

What is CTVQ™?

CTVQ™ (Computed Tomography Ventilation Quantification) is a cutting-edge, FDA-cleared software technology that delivers critical insights into both ventilation and perfusion from computed tomography (CT) scans. The technology allows healthcare providers to obtain quantified, actionable data that traditional imaging methods typically cannot offer. Such insights are becoming increasingly important for effective diagnosis, treatment planning, and long-term patient monitoring.

In an impressive demonstration of the product’s potential, four notable U.S. academic medical centers—Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health—adopted CTVQ™ within just four months following its FDA clearance. This rapid uptake demonstrates the growing recognition of the unique value that CTVQ™ brings to modern healthcare, fulfilling the demand from clinicians seeking enhanced imaging capabilities.

Strategic Use of Funds

The freshly acquired funding will focus on scaling up the deployment of CTVQ™ within U.S. hospitals and health systems. Key objectives for utilizing these funds include:

• - Increasing Commercial Presence: Strengthening the product's footprint across U.S. academic medical centers by promoting a multidisciplinary approach to its use.
• - Customer Support and Training: Providing comprehensive support, training, and resources to assist hospitals in seamlessly integrating CTVQ™ into their existing clinical workflows.
• - Ongoing R&D Initiatives: Further enhancing the technology leadership of 4DMedical through continuous investment in research and product development, ultimately expanding its capabilities in functional lung imaging.
• - Operational Growth: Ensuring operational flexibility to accommodate additional growth opportunities and sustained partnerships within the clinical community.

Additionally, 4DMedical reported a robust cash position of over US$130 million (AU$200 million), positioning the company optimally to pursue its U.S. expansion strategies while reinforcing its installed user base.

Integration with Existing Infrastructure

Unique to 4DMedical's approach is the Software-as-a-Service (SaaS) model under which CTVQ™ is provided, allowing smooth integration into existing hospital infrastructures. The company has also established strategic partnerships to further promote broader adoption and integration pathways for its technology. One notable collaboration includes a partnership with Philips, aimed at enhancing the distribution and utilization of CTVQ™.

Health systems interested in adopting CTVQ™ can reach out to 4DMedical for more information on implementation, workflow considerations, and product demonstrations. This continued commitment from 4DMedical highlights its status as a leader in advanced respiratory imaging technologies, further supporting clinicians in the quest for enhanced diagnostic accuracy and treatment efficacy.

About 4DMedical

4DMedical Limited (ASX4DX) stands at the forefront of medical technology, specializing in the development and deployment of advanced software solutions for cardiothoracic imaging. Their products leverage proprietary algorithms and artificial intelligence to generate deep, quantitative insights from routine imaging data, thus enabling healthcare professionals to assess lung function and cardiopulmonary conditions with unprecedented precision. Through their innovative solutions, the company aims to assist pulmonologists, radiologists, and other medical teams in delivering better patient outcomes by providing actionable, patient-specific information to inform clinical decisions.

In conclusion, with the newly acquired funding, 4DMedical is poised to make significant advances in respiratory imaging, paving the way for advancements in both diagnostics and treatment options for patients with lung diseases.